The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
Decades of market research reveals that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Is PTC Therapeutics Stock A Buy?
PTC Therapeutics stock reclaimed its 50-day moving average and is working on a consolidation with a 40.69 entry. See if the biotech stock can break out in heavy trading.
The biotech company posted 0% EPS growth last quarter, while sales growth came in at -13%.
PTC Therapeutics stock holds the No. 152 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, SIGA Technologies and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
